TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26727825
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of triamcinolone acetonid 4 mg/0.1 mL (Kenalog)
Study: 23460711
Drug: Fluorouracil (FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FU) ‐based chemotherapy with irinotecan (IRI)
Study: 19375557
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) with antiglycemic medications
Study: 17298589
Drug: Nateglinide +
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nateglinide + insulin glargine
Study: 17298589
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + insulin glargine
Study: 11377114
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment sooner
Study: 3893389
Drug: Albumin infusion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin infusion when COP fell below 24 cm H2O
Study: 3893389
Drug: Albumin infusion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin infusion when COP fell below 29 cm H2O
Study: 25352870
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment guidelines (STG) intervention group
Study: 23600305
Drug: Proton-photon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-photon therapy with proton beam 220Mev, focal dose of 28-28.8 Gy-eq for 8, 5 or 3 fractions (3, 4 or 5.5 Gy-eq)
Study: 23600305
Drug: Proton-photon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-photon therapy
Study: 18627368
Drug: Interrupted sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interrupted sevoflurane administration (SevoI)
Study: 18627368
Drug: Continuous sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous sevoflurane administration (SevoC)
Study: 10451167
Drug: Loperamide (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (initial dose of 4 mg, followed by 2 mg after each unformed stool, up to 8 mg/d) plus Oral Rehydration Therapy (ORT) (500 mL initially, followed by 250 mL after each subsequently passed unformed stool, up to 1,000 mL per 24 hours)
Study: 10451167
Drug: Loperamide (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (initial dose of 4 mg, followed by 2 mg after each unformed stool, up to 8 mg/d)
Study: 7575286
Drug: Topical antifungals
Normalized name: Imidazole and triazole derivatives, topical antifungals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antifungals (nystatin and amphotericin B suspensions)
Study: 30302465
Drug: Ubiquinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol (200 mg d‐1)
Study: 30302465
Drug: Ubiquinone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinone (200 mg d‐1)
Study: 22795238
Drug: Intra-articular contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular contrast injection only
Study: 15591082
Drug: Viscoelastic gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscoelastic gel
Study: 8890060
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (debridement only)
Study: 1503621
Drug: Sequential immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential immunosuppressive therapy (alternative therapy after no or minimal response)
Study: 6366617
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (50 mg every three weeks for two years)
Study: 17368095
Drug: Glutamate injection
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate injection
Study: 24237929
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem cream
Study: 19708174
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy throughout pregnancy
Study: 19708174
Drug: No metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No metformin therapy throughout pregnancy (Control)
Study: 17977295
Drug: Daily topical
Normalized name: Clindagel 1 % Once-Daily Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily topical applications of a dental cream containing CPP‐ACP (Topacal) for 3 months followed by a 3‐month period of daily toothbrushing with fluoridated dentifrice.
Study: 17977295
Drug: Daily 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 0.05% sodium fluoride mouthwash combined with fluoridated dentifrice for 6 months.
Study: 15903281
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no supplementary medication)
Study: 12553505
Drug: Indomethacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (2 x 50 mg a day)
Study: 1198015
Drug: Stellate ganglion
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stellate ganglion block with 10 ml of 0.5% Marcaine
Study: 1198015
Drug: Intra articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra articular hydrocortisone injection (50 mg of hydrocortisone acetate into the glenohumeral joint)
Study: 30095747
Drug: Plasma interleukin-1
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 0
Study: 30095747
Drug: Plasma interleukin-1
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels across all days
Study: 30095747
Drug: Plasma interleukin-1
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 2
Study: 30095747
Drug: Plasma interleukin-1
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels on day 1
Study: 30095747
Drug: Plasma interleukin-1
Normalized name: interleukin-1, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma interleukin-1 receptor antagonist (IL-1ra) levels
Study: 28962661
Drug: Cinnamomum zeylanicum
Normalized name: Cinnamomum camphora resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamomum zeylanicum extract (250 mg)
Study: 28962661
Drug: Cinnamomum zeylanicum
Normalized name: Cinnamomum camphora resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamomum zeylanicum extract (500 mg)
Study: 26383034
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and minimal nontraditional acupuncture (minimally active penetrating)
Study: 15871313
Drug: Topical eutectic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eutectic mixture of local anesthetics (EMLA)
Study: 15871313
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (LMX)
Study: 12587324
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nebivolol and enap
Study: 7037505
Drug: Nine daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine daily injections of fast‐acting insulin for ten days (group B)
Study: 7037505
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with one or two daily doses of insulin (group A)
Study: 24331115
Drug: DHEA 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 75 mg daily for 12 weeks
Study: 15455733
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg B.I.D. with scaling and root planing (SRP)
Study: 11306234
Drug: BV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BV treatment in high-risk women (previous preterm delivery)
Study: 11306234
Drug: BV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BV treatment in high-risk women (not having BV)
Study: 11306234
Drug: Routine BV
Normalized name: Bifidobacterium longum bv. infantis whole
DrugBank: Bifidobacterium longum infantis (DB14222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine BV screening and treatment
Study: 811237
Drug: Intramuscular and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular and oral bromhexine for 5 days
Study: 811237
Drug: Intramuscular and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular and oral bromhexine for 5 days in high-risk patients
Study: 25331270
Drug: Red Bull
Normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Bull Energy drink (caffeine at 2 mg/kg body weight)
Study: 21712623
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no APF gel application)
Study: 19350335
Drug: Ponseti treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponseti treatment group
Study: 16689810
Drug: Alcohol-based gels
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol-based gels with varying glycerine concentrations and alcohol grades (70% ethanol)
Study: 16689810
Drug: Isopropanol-based gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopropanol-based gel
Study: 7905376
Drug: Levocabastine eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine eye drops (0.5 mg/ml) given from twice to four times daily for 1-8 weeks
Study: 7905376
Drug: Levocabastine eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine eye drops (0.5 mg/ml)
Study: 3066142
Drug: Nimodipine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (intravenous treatment)
Study: 23106907
Drug: Standardized physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physiotherapy protocol (mask with positive expiratory pressure of 10 cm H2O, expiratory rib cage compression, coughing, lifting upper limbs, ambulation, starting within 4 hours post-surgery, 3 times daily)
Study: 22017069
Drug: Calcipotriene 0.005%-betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment with hydrogel patch
Study: 22017069
Drug: Calcipotriene 0.005%-betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment without hydrogel patch
Study: 18435781
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human insulin (Exubera, EXU) with standard care
Study: 9688485
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of cefuroxime intravenously at cord clamping (n = 59)
Study: 25124964
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group using 'TOPHAT655' unit with 21, 5 mW diode lasers (655 ± 5 nm) and 30 LEDs (655 ± 20 nm), treated at home every other day for 16 weeks (60 treatments, 67 J/cm² irradiance, 25 minute treatment, 2.9 J dose).
Study: 25124964
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment group using an identical unit containing incandescent red lights.
Study: 17488308
Drug: Vardenafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (10 mg for 4 weeks, titrated to preferred dose of 5, 10, or 20 mg during the next 8 weeks, maintained at preferred dose for 14 weeks)
Study: 9678530
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.1 IU/kg s.c.)
Study: 2729170
Drug: Aspartame (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (10 mg aspartame/kg)
Study: 29720202
Drug: Standard acquisition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard acquisition parameters with double dose (0.2 mmol/kg) Gadovist and 4 mm slice thickness.
Study: 29720202
Drug: Reduced, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced, single dose of GBCA (n=10), half slice thickness (n=10), or on a 3T scanner (n=10).
Study: 28705252
Drug: PGx-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGx-guided treatment (n=155)
Study: 28705252
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU, control group, n=161)
Study: 26179186
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with defibrillator
Study: 24119702
Drug: Probiotics (Golden
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Golden Bifid, 3.5 g for 3 times per day) for 21 days
Study: 24119702
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional treatment and enteral nutrition)
Study: 20363036
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments delivered to patients
Study: 20363036
Drug: Therapeutic trials
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic trials with chemotherapy agents
Study: 12233984
Drug: Contingent monetary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingent monetary reinforcement (CM) combined with 21 mg transdermal nicotine
Study: 12233984
Drug: Contingent monetary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingent monetary reinforcement (CM) combined with placebo patch
Study: 12233984
Drug: Noncontingent reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncontingent reinforcement combined with placebo patch
Study: 7501142
Drug: Overall surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall surgical therapy
Study: 2176948
Drug: Control (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (in vitro measurement without drug)
Study: 23581720
Drug: B-LAL (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-LAL (lansoprazole 30 mg b.i.d., amoxicillin 1000 mg b.i.d., levofloxacin 500 mg daily, bismuth potassium citrate 220 mg b.i.d. for 14 days)
Study: 23581720
Drug: LAL (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAL (lansoprazole 30 mg b.i.d., amoxicillin 1000 mg b.i.d., levofloxacin 500 mg daily for 14 days)
Study: 20581422
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of dialysis (when estimated GFR was 10.0 to 14.0 ml per minute)
Study: 20581422
Drug: Late initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Late initiation of dialysis (when estimated GFR was 5.0 to 7.0 ml per minute)
Study: 18430999
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (10, 20, 40, or 60 IU)
Study: 2961356
Drug: Oral Cl2MDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Cl2MDP (1600 mg twice daily for 16 weeks)
Study: 2961356
Drug: Intravenous Cl2MDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Cl2MDP (2.5 mg/kg on the first day and 5 mg/kg daily for up to 6 days)
Study: 29053231
Drug: Nasal glucagon
Normalized name: glucagon Nasal Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal glucagon (NG) administered while experiencing nasal congestion (Cohort 1)
Study: 29053231
Drug: Nasal glucagon
Normalized name: glucagon Nasal Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal glucagon (NG) administered after treatment with oxymetazoline (Cohort 2)
Study: 29053231
Drug: Nasal glucagon
Normalized name: glucagon Nasal Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal glucagon (NG) administered with nasal congestion (Cohort 1)
Study: 29053231
Drug: Nasal glucagon
Normalized name: glucagon Nasal Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal glucagon (NG) administered after recovery from cold symptoms (Cohort 1)
Study: 29053231
Drug: Nasal glucagon
Normalized name: glucagon Nasal Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal glucagon (NG) administered with concomitant nasal decongestant (Cohort 2)
Study: 24942096
Drug: Buccal sulcus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal sulcus approach
Study: 24942096
Drug: Intranasal approach
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal approach
Study: 18524691
Drug: 10-session, therapist-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-session, therapist-administered CBT
Study: 18524691
Drug: 4-session, patient-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-session, patient-administered CBT
Study: 9851273
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg weekly i.m. injections for 12 months
Study: 9851273
Drug: Gold sodium
Normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold sodium thiomalate (GSTM) 50 mg weekly i.m. injections for 12 months
Study: 2643296
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2 by 48‐h continuous i.v. infusion every 3 weeks)
Study: 2643296
Drug: Epirubicin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (90 mg/m2 by 48‐h continuous i.v. infusion every 3 weeks)
Study: 2643296
Drug: Epirubicin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (90 mg/m2 by bolus every 3 weeks)
Study: 766791
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine with adrenaline 5 mug/ml
Study: 766791
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine with adrenaline 5 mug/ml
Study: 6105336
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg PolyA.PolyU intravenously per week for 6 weeks
Study: 30712716
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (4 capsules of 500 mg daily for 3 days)
Study: 30712716
Drug: Trimethoprim-sulfamethoxazole (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (standard antimicrobial treatment)
Study: 30712716
Drug: Starch (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch (placebo, 4 capsules daily for 3 days)
Study: 29093283
Drug: S‐NAC (surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐NAC (surgery with N-acetylcysteine 600 mg)
Study: 23406981
Drug: Citicoline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (1 g/day) for 12 months
Study: 18427456
Drug: Galantamine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (maximum dose 16 mg/day)
Study: 15701301
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicines (CAM)
Study: 11969062
Drug: Alternative medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternative medicines with inhibitory effects on the coagulation cascade
Study: 11969062
Drug: Alternative medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternative medicines affecting blood pressure
Study: 11969062
Drug: Alternative medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternative medicines affecting cardiac function
Study: 11969062
Drug: Alternative medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternative medicines causing sedation
Study: 11969062
Drug: Alternative medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternative medicines with potential to alter electrolyte levels
Study: 11969062
Drug: Herbs recognized
Normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbs recognized to interact with pharmaceuticals
Study: 9831574
Drug: Milk plus
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk plus one designated food daily
Study: 2680178
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate cream twice daily
Study: 2680178
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate cream once daily with base cream in the evening
Study: 765293
Drug: Cyclazocine, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclazocine, 4 mg administered daily
Study: 765293
Drug: Naloxone, 500-2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone, 500-2,000 mg administered on a contingent basis
Study: 21303569
Drug: Fe-fortified fruit
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe-fortified fruit juice (500 ml/d providing 18 mg Fe/d)
Study: 21303569
Drug: Placebo fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo fruit juice (500 ml/d)
Study: 19494532
Drug: Metformin (1,700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,700 mg/day) for 12 weeks
Study: 19494532
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/day) for 12 weeks
Study: 19494532
Drug: Simvastatin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (maximum dose 20 mg/day) in a subset of patients (n = 9)
Study: 17719288
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (including ramipril)
Study: 12508627
Drug: Directly Observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Observed Therapy Short Course (DOTS)